Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Urban

Showing results (91-100 of 134) with videos related to

Pageof 14
Sort By:
Gut|December 9, 2017
Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivoKatja Giersch, Oliver D Bhadra, Tassilo Volz, et al.
Nature Biotechnology|February 26, 2008
Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope proteinJoerg Petersen, Maura Dandri, Walter Mier, et al.
Journal of Hepatology|February 10, 2024
Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsiesLena Allweiss, Annika Volmari, Vithika Suri, et al.
Hepatology (Baltimore, Md.)|August 5, 2015
Present and future therapies of hepatitis B: From discovery to cureT Jake Liang, Timothy M Block, Brian J McMahon, et al.
Plos One|September 13, 2011
The novel immunosuppressive protein kinase C inhibitor sotrastaurin has no pro-viral effects on the replication cycle of hepatitis B or C virusThomas von Hahn, Andreas Schulze, Ivan Chicano Wust, et al.
Gut|January 27, 2023
Quantification of the hepatitis B virus cccDNA: evidence-based guidelines for monitoring the key obstacle of HBV cureLena Allweiss, Barbara Testoni, Mei Yu, et al.
The Journal of Infectious Diseases|January 30, 2020
Blocking Entry of Hepatitis B and D Viruses to Hepatocytes as a Novel Immunotherapy for Treating Chronic InfectionsPanagiota Maravelia, Lars Frelin, Yi Ni, et al.
Journal of Hepatology|May 2, 2016
Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa studyPavel Bogomolov, Alexander Alexandrov, Natalia Voronkova, et al.
Frontiers in Immunology|December 25, 2023
Hepatitis D infection induces IFN-β-mediated NK cell activation and TRAIL-dependent cytotoxicityChristopher Groth, Jovana Maric, Irene Garcés Lázaro, et al.
Gut|August 17, 2022
Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infectionsRani Burm, Panagiota Maravelia, Gustaf Ahlen, et al.
Pageof 14

Showing results (91-100 of 134) with videos related to

Sort By:
Pageof 14
Gut|December 9, 2017
Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivoKatja Giersch, Oliver D Bhadra, Tassilo Volz, et al.
Nature Biotechnology|February 26, 2008
Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope proteinJoerg Petersen, Maura Dandri, Walter Mier, et al.
Journal of Hepatology|February 10, 2024
Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsiesLena Allweiss, Annika Volmari, Vithika Suri, et al.
Hepatology (Baltimore, Md.)|August 5, 2015
Present and future therapies of hepatitis B: From discovery to cureT Jake Liang, Timothy M Block, Brian J McMahon, et al.
Plos One|September 13, 2011
The novel immunosuppressive protein kinase C inhibitor sotrastaurin has no pro-viral effects on the replication cycle of hepatitis B or C virusThomas von Hahn, Andreas Schulze, Ivan Chicano Wust, et al.
Gut|January 27, 2023
Quantification of the hepatitis B virus cccDNA: evidence-based guidelines for monitoring the key obstacle of HBV cureLena Allweiss, Barbara Testoni, Mei Yu, et al.
The Journal of Infectious Diseases|January 30, 2020
Blocking Entry of Hepatitis B and D Viruses to Hepatocytes as a Novel Immunotherapy for Treating Chronic InfectionsPanagiota Maravelia, Lars Frelin, Yi Ni, et al.
Journal of Hepatology|May 2, 2016
Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa studyPavel Bogomolov, Alexander Alexandrov, Natalia Voronkova, et al.
Frontiers in Immunology|December 25, 2023
Hepatitis D infection induces IFN-β-mediated NK cell activation and TRAIL-dependent cytotoxicityChristopher Groth, Jovana Maric, Irene Garcés Lázaro, et al.
Gut|August 17, 2022
Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infectionsRani Burm, Panagiota Maravelia, Gustaf Ahlen, et al.
Pageof 14